Prof. Songbing He | Tumor Immunology | Best Researcher Award

Prof. Songbing He | The First Affiliated Hospital of Soochow University | China

Dr. Songbing He is a distinguished colorectal cancer researcher 🏥 and surgeon 🔬 at The First Affiliated Hospital of Soochow University, China 🇨🇳. With a strong background in immunomodulation 🦠 and immunometabolism 🔥, he has contributed significantly to both basic and clinical research 📚. His work explores innovative treatments 💡 for colorectal cancer, integrating immunotherapy 💉 and metabolism-based interventions ⚡. Dr. He has held key positions in prestigious institutions, including Washington University in St. Louis 🇺🇸. His research has led to impactful publications 📝, accumulating over 200 citations 🔢. As a dedicated academic 🎓 and clinician 🏥, Dr. He continues to advance the field of gastrointestinal oncology 🏆.

Professional Profile:

Google Scholar

SCOPUS

Suitability for Best Researcher Award

Dr. Songbing He is a renowned researcher and surgeon specializing in colorectal cancer at The First Affiliated Hospital of Soochow University, China 🏥. His expertise in immunomodulation 🧬 and immunometabolism 🔥 has greatly advanced colorectal cancer research. His innovative approach 🚀—integrating immunotherapy 💉 with metabolism-based interventions—highlights his pioneering role in developing novel cancer treatment strategies.

Education & Experience 🎓💼

Ph.D. in Surgery (2009-2012) 🏥 – Soochow University, China
Master’s Degree in Surgery (2003-2006) 🩺 – Soochow University, China
Bachelor’s Degree in Clinical Medicine (1998-2003) 📚 – Jiangsu University, China
Research Fellow (2013-Present) 🔬 – Washington University in St. Louis, USA
Postdoctoral Researcher (2012-2013) 🧪 – Shanghai Jiao Tong University, China
Attending Doctor & Lecturer (2009-2013) 👨‍⚕️ – The First Affiliated Hospital of Soochow University
Resident & Teaching Assistant (2006-2009) 🏥 – The First Affiliated Hospital of Soochow University

Professional Development 🌎📖

Dr. He’s career is marked by continuous learning and global collaborations. At Washington University, he explored the intersection of nutrition, immunology, and colorectal cancer, fostering advancements in immunometabolism. His postdoctoral tenure at Shanghai Jiao Tong University further refined his expertise in tumor immunology. As a lecturer and attending physician, he has mentored young researchers and medical students, contributing to medical education. His participation in international conferences and editorial roles in scientific journals reflects his dedication to knowledge dissemination. Through innovative research and interdisciplinary collaborations, Dr. He remains at the forefront of colorectal cancer advancements.

Research Focus 🔬🦠

Dr. Songbing He’s research primarily revolves around colorectal cancer with a focus on tumor immunology and metabolism. He investigates how the immune system interacts with tumor cells and explores ways to manipulate these interactions for improved therapies. His expertise extends to immunometabolism, where he examines how metabolic changes within immune cells affect cancer progression. Additionally, he explores novel biomarkers for early detection and personalized treatment strategies. His work integrates basic science with clinical applications, bridging the gap between laboratory discoveries and patient care, ultimately aiming for more effective and less toxic cancer treatments.

Awards & Honors 🏆🎖

Outstanding Researcher Award 🏅 – Soochow University
Best Paper Award 📜 – International Colorectal Cancer Conference
Excellent Young Scholar Grant 💰 – National Natural Science Foundation of China
Top Reviewer Recognition 🏅 – Leading Oncology Journals
Travel Grant for Young Scientists ✈️ – International Immunology Congress

Publication Top Notes :

📖 Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity | 👥 928 citations | 🏛️ Cell Metabolism

📖 Distribution and clinical significance of Th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients | 👥 174 citations | 🏛️ International Journal of Molecular Sciences

📖 Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species | 👥 121 citations | 🏛️ Toxicology Letters

📖 Clinicopathologic Significance of HIF‐1α, CXCR4, and VEGF Expression in Colon Cancer | 👥 101 citations | 🏛️ Journal of Immunology Research

📖 Downregulation of enhancer of zeste homolog 2 (EZH2) is essential for the induction of autophagy and apoptosis in colorectal cancer cells | 👥 87 citations | 🏛️ Genes

📖 MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway | 👥 83 citations | 🏛️ International Journal of Molecular Medicine

Prof. Dr. Yanchuan Li | Nanjing Medical University | China

Dr. Yanchuan Li (李砚川), born in 1985 in Pingxiang, Jiangxi, is a distinguished cancer immunology researcher. He earned his Ph.D. in Biochemistry and Molecular Biology from Peking Union Medical College (Tsinghua University School of Medicine) in 2016 under the mentorship of Academician Linfang Wang and Prof. Shao-Cong Sun. Currently, he is a Professor and Ph.D. advisor at Nanjing Medical University, focusing on tumor and immune research. His expertise spans lymphocyte receptor signaling, CAR-NKT cell therapy, and molecular immunology. His groundbreaking research has been published in Cell Research, Blood, JEM, and Nature Communications. He also serves as a reviewer for top journals like Cellular & Molecular Immunology, Nucleic Acids Research, and Molecular Therapy. 🎓🔍

Suitability for Best Researcher Award

Dr. Yanchuan Li is a highly suitable candidate for a Best Researcher Award due to his exceptional contributions to cancer immunology and molecular immunology. Dr. Li’s expertise in lymphocyte receptor signaling, CAR-NKT cell therapy, and tumor immunology has significantly advanced the understanding of immune regulation in cancer. His research impacts both fundamental immunological mechanisms and translational applications, making him a distinguished figure in the field.

Education & Experience 📚👨‍🔬

2012-2016 🎓 Ph.D. in Biochemistry & Molecular Biology – Peking Union Medical College (Tsinghua University School of Medicine)

2014-2016 🌎 Visiting Ph.D. Scholar – MD Anderson Cancer Center, USA (CSC Scholarship)

2016-2021 🧪 Postdoctoral Research Fellow – MD Anderson Cancer Center, USA

2021-2022 🏥 Research Scientist – MD Anderson Cancer Center, USA

2022-2023 🔬 Research Associate – Baylor College of Medicine, USA

2023-Present 🎓 Professor & Ph.D. Supervisor – Nanjing Medical University

Professional Development 🔬📈

Dr. Li’s research bridges fundamental tumor immunology and translational medicine, employing cell culture, gene manipulation, proteomics, and multi-omics approaches. His work utilizes CRISPR/Cas9 screening, single-cell analysis, and knockout mouse models to uncover key immune signaling mechanisms. His significant contributions to B cell function, CAR-NKT therapy, and immune regulation in major diseases are paving the way for innovative cancer treatments. He has played a key role in developing CAR-NKT cell therapies, including a clinical trial for relapsed neuroblastoma. His dedication to scientific excellence and interdisciplinary collaboration is shaping the future of cancer immunotherapy. 🏥🧬💡

Research Focus 🔍🦠

Dr. Li’s research covers tumor immunology and translational medicine, with key interests in:
1️⃣ B Cell Function & Autoimmunity – Exploring B cell activation in diseases like SLE & B cell leukemia. 🔬🦠
2️⃣ CAR-NKT Cell Therapy – Engineering NKT cells for safer and more effective cancer immunotherapy. 🎯💉
3️⃣ Molecular Mechanisms of Major Diseases – Utilizing multi-omics & disease models to investigate cancer progression, autoimmune disorders, and drug response. 🧪📊
4️⃣ Advanced Immuno-Analytical Techniques – Developing single-cell spatial transcriptomics, CRISPR-based screens, and novel proteomics to revolutionize cancer research. 🔍🔬

Publication Top Notes:

📢 Proinflammatory TLR signalling is regulated by a TRAF2-dependent proteolysis mechanism in macrophages – Cited by 97 🔬
🧬Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results – Cited by 87 🏥
🦠 TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis – Cited by 78 🧫
🛡Cell intrinsic role of NF-κB-inducing kinase in regulating T cell-mediated immune and autoimmune responses – Cited by 67 🏋️
🧩 Preventing abnormal NF-κB activation and autoimmunity by Otub1-mediated p100 stabilization – Cited by 44 🏗
🦠 NIK signaling axis regulates dendritic cell function in intestinal immunity and homeostasis – Cited by 44 🦠
🔥 Peli1 facilitates NLRP3 inflammasome activation by mediating ASC ubiquitination – Cited by 43 🚀
🧠 Microglia promote autoimmune inflammation via the noncanonical NF-κB pathway – Cited by 42 🧠
🌿 Protective effect of melatonin on cigarette smoke‐induced restenosis in rat carotid arteries after balloon injury – Cited by 40 🌙
🦠 Intestinal epithelial TBK1 prevents differentiation of T-helper 17 cells and tumorigenesis in mice – Cited by 30 🏥